Cipla, one of the world’s leading generic pharmaceutical companies in collaboration with Drugs for Neglected Diseases Initiative (DNDi) is planning to launch the Fixed-Dose combination of ‘Artesunate (AS)1 + Mefloquine (MQ)2’ for the treatment of uncomplicated P. falciparum malaria. The combination of AS and MQ is proven to be a safe, rapid and reliably effective treatment for uncomplicated P. falciparum malaria and is recommended by the World Health Organization (WHO).
Targeted as an option for treating resistant uncomplicated falciparum malaria, the new combination simplifies the patient’s treatment with a single dose of 1 or 2 tablets for 3 days, ensuring that the drugs are taken together and in correct proportions. This new fixed-dose combination treatment will be introduced in India under the brand name ‘MEFLIAM Plus’.
Through an innovative partnership supported and facilitated by DNDi in 2008, Cipla entered into an agreement with the Brazilian government-owned pharmaceutical company Farmanguinhos/Fiocruz to introduce the new fixed-dose combination in Asian and African countries. The product will be launched in India and Malaysia soon where it has already been registered.
The drugs for the fixed-dose combination (ASMQ) are being manufactured in Cipla’s world class manufacturing unit in Patalganga, which are approved by WHO-Geneva, USFDA, MHRA-UK and various other regulatory bodies.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1821.30 |
Dr. Reddys Lab | 1180.00 |
Cipla | 1544.80 |
Lupin | 2077.90 |
Zydus Lifesciences | 890.60 |
View more.. |